Age-Related Hormonal Changes and Sexual Function

Aging brings predictable changes to the hormonal systems that support sexual health. These changes are natural, but understanding them empowers individuals and their healthcare providers to intervene when changes significantly impact quality of life.

Hormonal Changes in Women

Perimenopause and Menopause

The menopausal transition typically begins in the mid-40s and involves progressive decline in ovarian estrogen and progesterone production. Key impacts on sexual health include:

• Vaginal atrophy, Reduced estrogen leads to thinning of vaginal tissue, decreased lubrication, and increased susceptibility to irritation, collectively known as genitourinary syndrome of menopause (GSM)
• Reduced desire, Declining estrogen and testosterone contribute to decreased libido in many women
• Orgasmic changes, Some women report reduced orgasmic intensity or increased difficulty reaching orgasm

A review published in JAMA noted that up to 50% of postmenopausal women report vaginal dryness and dyspareunia (painful intercourse), yet fewer than half seek treatment.

Adrenal Androgen Decline

In addition to ovarian changes, adrenal production of DHEA and testosterone declines with age. Since these androgens contribute to desire in women, their decline can compound the effects of estrogen loss.

Hormonal Changes in Men

Late-Onset Hypogonadism

Often informally called "andropause," late-onset hypogonadism describes the gradual decline in testosterone that occurs in aging men. Unlike menopause, which involves a relatively abrupt hormonal shift, male testosterone decline is progressive and variable.

Research indicates:

• Total testosterone declines approximately 1-2% per year after age 30
• Free testosterone (the biologically active fraction) declines more steeply due to age-related increases in sex hormone-binding globulin (SHBG)
• By age 70, approximately 30% of men have testosterone levels below the normal range

Impact on Sexual Function

Low testosterone in older men is associated with:

• Reduced sexual desire and frequency of sexual thoughts
• Erectile dysfunction (though vascular causes often coexist)
• Decreased ejaculatory volume
• Reduced intensity of orgasm

Importantly, erectile dysfunction in aging men is frequently multifactorial, involving vascular, neurological, hormonal, and psychological components.

Evidence-Based Interventions

For Women

• Vaginal estrogen therapy, Local estrogen application is effective for GSM symptoms with minimal systemic absorption. Multiple formulations are available (cream, ring, tablet).
• Systemic hormone therapy, For women with bothersome vasomotor symptoms and sexual concerns, systemic estrogen (with progesterone for women with a uterus) can address multiple symptoms simultaneously.
• Testosterone therapy, Although not FDA-approved for women in the United States, transdermal testosterone has shown efficacy for hypoactive sexual desire in postmenopausal women in well-designed clinical trials. International guidelines support its use in appropriate patients.
• Ospemifene, A selective estrogen receptor modulator (SERM) approved for dyspareunia associated with menopause.

For Men

• Testosterone replacement therapy, Indicated for men with confirmed hypogonadism (low testosterone plus symptoms). Benefits include improved desire, erectile function, and overall sexual satisfaction.
• PDE5 inhibitors, Sildenafil, tadalafil, and similar medications remain first-line therapy for erectile dysfunction in aging men.
• Lifestyle optimization, Exercise, weight management, sleep, and cardiovascular health directly support sexual function and can slow age-related decline.

The Importance of Comprehensive Assessment

Age-related sexual changes are often attributed solely to "getting older" without appropriate medical evaluation. A thorough assessment should include hormonal testing, cardiovascular evaluation, medication review, and psychological screening, as treatable causes are frequently identified.

Practical Takeaways

• Hormonal changes with aging are natural but not untreatable
• Both men and women benefit from comprehensive hormonal evaluation when experiencing sexual health changes
• Local and systemic hormonal therapies have strong evidence supporting their use in appropriate patients
• Lifestyle factors including exercise, weight management, and cardiovascular health play a significant role in maintaining sexual function with age
• Many patients delay seeking care unnecessarily; early evaluation allows for earlier intervention

---

*This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before beginning any new treatment. Individual results may vary.*

References

1. Danan ER, et al. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review. *Ann Intern Med.* 2024 Oct. PMID 39250810. [https://pubmed.ncbi.nlm.nih.gov/39250810/](https://pubmed.ncbi.nlm.nih.gov/39250810/)
2. Costa-Paiva L, et al. Genitourinary syndrome of menopause and sexual function, partner knowledge, and treatment. *Menopause.* 2025 Aug. PMID 40460391. [https://pubmed.ncbi.nlm.nih.gov/40460391/](https://pubmed.ncbi.nlm.nih.gov/40460391/)
3. Singh P, et al. Andropause: Current concepts. *Indian J Endocrinol Metab.* 2013 Dec. PMID 24910824. [https://pubmed.ncbi.nlm.nih.gov/24910824/](https://pubmed.ncbi.nlm.nih.gov/24910824/)
4. Jannini EA, et al. Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause. *Sex Med Rev.* 2018 Jul. PMID 29371146. [https://pubmed.ncbi.nlm.nih.gov/29371146/](https://pubmed.ncbi.nlm.nih.gov/29371146/)
5. Edwards D, et al. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is treatment for quality of life? *Climacteric.* 2016 Apr. PMID 26707589. [https://pubmed.ncbi.nlm.nih.gov/26707589/](https://pubmed.ncbi.nlm.nih.gov/26707589/)